
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
Professor José-Manuel Carrascosa-Carrillo is the Head of the Department of Dermatology, Hospital Universitario Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain, and has been Associate Professor at the Universitat Autònoma de Barcelona since 2009. He earned his medical degree at the Hospital Clínic i Provincial de Barcelona, Universitat de Barcelona, in 1991 and his PhD degree at the Universitat Autònoma de Barcelona in 2006.
Professor Carrascosa-Carrillo is responsible for the Psoriasis, Phototherapy/Photobiology, Contact Dermatitis and Eczema Department and the Psoriasis Unit at the Hospital Universitario Germans Trias i Pujol. He has been Principal Investigator/Clinical Investigator in more than 60 research projects/clinical trials, many of them multinational, multicentre studies related to biological therapies in psoriasis and atopic dermatitis.
Professor Carrascosa-Carrillo has authored or co-authored 214 articles in journals on dermatology or other medical specialties. He was Editor-in-Chief of Actas Dermo-sifiliográficas from 2010 to 2014 and is currently a reviewer for several peer-reviewed journals, including Journal of Investigative Dermatology, The Lancet, Journal of the European Academy of Dermatology and Venereology, British Journal of Dermatology, Journal of Crohn's and Colitis, Journal of Dermatological Science and Biodrugs. He has been Chairperson at more than 100 local and international meetings and has been invited to give more than 250 lectures (national/ international) at conferences, symposia and other events. Professor Carrascosa is the Chair of the Spanish Group of Psoriasis of the Spanish Academy of Dermatology and vice-president of the Academia Española de Dermatología y Venereología (AEDV). Moreover, he has been a member of the scientific board of the Skin Inflammation & Psoriasis International Network (SPIN) since 2015 and was on the organising committee of the 2019 and 2022 SPIN meetings in Paris. He has been recently elected as a councillor of the International Psoriasis Council (IPC).
Watch Prof Lars Erik Kristensen and Prof Frank Behrens discuss how MDA is a realistic treatment target in clinical practice and the barriers to achieving it for...
Treatment for PsA should target a broad range of musculoskeletal and extra-articular manifestations.1 Listen to Assoc. Prof Philipp Sewerin explain how MDA can...
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
axSpA is a complex disease with a significant burden on many aspects of daily life.1,2 Dive into the importance of ASAS40 for your patients with Dr Fabian Proft.
Watch Prof Robert Landewé discuss the importance of using ASDAS <2.1 as a treatment target for patients with axSpA.
Read our key takeaways from the 2022 ASAS-EULAR recommendations for the management of axSpA, presented as part of Dr Sofia Ramiro's workshop at UCB Summit 2023.